-
-
-
-
-
-
-
UBS Upgrades BioNTech (BNTX) to Buy
-
-
-
-
-
-
-
BioNTech (BNTX) PT Lowered to $94 at Leerink Partners
-
-
-
-
-
-
-
BioNTech SE (BNTX) June 80 and September 55 puts active as share price down 17.7%
-
-
-
-
-
-
-
Goldman Sachs Upgrades BioNTech (BNTX) to Buy, 'at the nexus of these significant developments occurring in the oncology field'
-
-
-
-
-
-
-
Clear Street Reiterates Buy Rating on BioNTech (BNTX)
-
-
-
-
-
-
-
BioNTech SE (BNTX) Misses Q3 EPS by 22c; lifts guidance
-
-
-
-
-
-
-
CDC Panel Votes Against Requiring Prescriptions For Covid Shots - Bloomberg
-
458,124 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

